These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6440278)

  • 1. Principles of in vivo recovery and survival studies of VIII:C.
    Allain JP
    Scand J Haematol Suppl; 1984; 41():123-30. PubMed ID: 6440278
    [No Abstract]   [Full Text] [Related]  

  • 2. Principles of in vivo recovery and survival studies.
    Allain JP
    Scand J Haematol Suppl; 1984; 40():161-3. PubMed ID: 6433447
    [No Abstract]   [Full Text] [Related]  

  • 3. Calculations of factor VIII in vivo recovery and half-life.
    Kjellman H
    Scand J Haematol Suppl; 1984; 40():165-74. PubMed ID: 6433448
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients.
    Morfini M; Grasela TH; Longo G; Matucci M; Messori A; Vannini S; Rossi-Ferrini P
    Haematologica; 1985; 70(5):454-6. PubMed ID: 3937784
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo recovery of cryoprecipitated factor 8.
    Verstraete M; Lust A; Vermylen J
    Bibl Haematol; 1970; 34():9-17. PubMed ID: 5436359
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of 'single donor' factor VIII from plasma exchange donation.
    McLeod BC; Scott JP
    JAMA; 1984 Nov; 252(19):2726-9. PubMed ID: 6436520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
    Perret BA; Poorbeik M; Morell A
    Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII concentrate for hemophilia: comparison of two heat-treated products.
    Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH
    CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid.
    Weiss AE; Webster WP; Strike LE; Brinkhous KM
    Transfusion; 1976; 16(3):209-14. PubMed ID: 936268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eloctate for hemophilia A.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):143-4. PubMed ID: 26445206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing rDNA products for treatment of hemophilia A.
    Kaufman RJ
    Trends Biotechnol; 1991 Oct; 9(10):353-9. PubMed ID: 1367761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic evaluation of four Factor VIII concentrates by model-independent methods.
    Matucci M; Messori A; Donati-Cori G; Longo G; Vannini S; Morfini M; Tendi E; Rossi-Ferrini PL
    Scand J Haematol; 1985 Jan; 34(1):22-8. PubMed ID: 3918340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
    Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effectiveness of a high-yield factor VIII concentrate prepared in a blood bank.
    Rock G; Smiley RK; Tittley P; Palmer DS
    N Engl J Med; 1984 Aug; 311(5):310-3. PubMed ID: 6429536
    [No Abstract]   [Full Text] [Related]  

  • 17. Individualization of Factor VIII dosage.
    Messori A; Longo G; Morfini M; Donati-Cori G; Matucci M; Ruffo S; Tendi E; Vannini S
    J Clin Hosp Pharm; 1984 Jun; 9(2):95-103. PubMed ID: 6430968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Substitution treatment in hemophilia. Critical measures and complications].
    Schimpf K
    Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical aspects of hemophilia and von Willebrand's disease.
    Ciavarella D; Counts RB
    Am J Med Technol; 1983 Dec; 49(12):850-4. PubMed ID: 6422754
    [No Abstract]   [Full Text] [Related]  

  • 20. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.